Roth Capital Reiterates Buy on Insmed, Maintains $212 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 91.2%

Neg 0% Neu 91.2% Pos 0%

Roth Capital analyst Adam Walsh reiterates Insmed (NASDAQ:INSM) with a Buy and maintains $212 price target.

Comments

No comments yet. Be the first!